Karanwal Arun B, Parikh Bharat J, Goswami Parijat, Panchal Harsha P, Parekh Bhavesh B, Patel Kaushal B
Department of Medical and Pediatric Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Indian J Med Paediatr Oncol. 2013 Apr;34(2):85-8. doi: 10.4103/0971-5851.116184.
The aim of this study was to study clinical profile with bacterial spectrum and susceptibility patterns of pathogens in culture positive febrile neutropenic (FN) patients of hematological malignancies.
We retrospectively reviewed the medical records of 23 hematological malignancy patients admitted with chemotherapy induced febrile neutropenia with culture positive results, at our institute between June 2011 and December 2011.
A total of 23 patients were studied 12 males and 11 females, with a median age of 35 years. Most common diagnosis was acute leukemia (78%) with the majority of patients developing febrile neutropenia during the induction phase of treatment. Most common presenting symptoms were fever, cough, dyspnea, and diarrhea. Primary site of infection was not found in 47% of patients while the rest had lung, gastro-intestinal and skin/soft-tissue infection. Overall 23 organisms were isolated during the study period, from blood (56%), sputum (46%), stool (23%), and nasal swab from one patient. Gram negative bacteria accounted for 78% of organisms while gram positive organisms accounted for 22% of the total isolates. The most common organisms were: Escherichia coli (43%), Staphylococcus aureus (22%), Pseudomonas aeruginosa (17.4%) and Klebsiella pneumonia (17.4%). Antibiotic sensitivity patterns of these bacteria were studied. Gram negative bacterial infections were associated with higher mortality (89%).
Induction phase of treatment in acute leukemia is the major cause of FN in hematological malignancies at our institute and gram negative organisms are the predominant organisms with E. coli as major isolate while S. aureus represents the most common gram positive organism. Amikacin and cefoperazone/sulbactum appears to be initial antibiotic appropriate to cover most gram negative pathogens while vancomycin to be added for suspected gram positive infections. FN represents a major cause of morbidity and mortality in hematological malignancy patients, high index of suspicion and early empirical antibiotics with supportive care are main interventions to reduce high mortality for these patients. Antibiotics should be modified according to culture sensitive report as soon as possible.
本研究旨在探讨血液系统恶性肿瘤伴培养阳性的发热性中性粒细胞减少症(FN)患者的临床特征、细菌谱及病原体药敏模式。
我们回顾性分析了2011年6月至2011年12月期间在我院收治的23例因化疗导致发热性中性粒细胞减少且培养结果呈阳性的血液系统恶性肿瘤患者的病历。
共研究了23例患者,其中男性12例,女性11例,中位年龄为35岁。最常见的诊断为急性白血病(78%),大多数患者在治疗诱导期出现发热性中性粒细胞减少。最常见的症状为发热、咳嗽、呼吸困难和腹泻。47%的患者未发现感染的原发部位,其余患者有肺部、胃肠道及皮肤/软组织感染。在研究期间共分离出23种病原体,分别来自血液(56%)、痰液(46%)、粪便(23%)以及1例患者的鼻拭子。革兰阴性菌占分离出病原体的78%,革兰阳性菌占总分离株的22%。最常见的病原体为:大肠埃希菌(43%)、金黄色葡萄球菌(22%)、铜绿假单胞菌(17.4%)和肺炎克雷伯菌(17.4%)。研究了这些细菌的抗生素敏感性模式。革兰阴性菌感染与较高的死亡率相关(89%)。
在我院,急性白血病的治疗诱导期是血液系统恶性肿瘤患者发生FN的主要原因,革兰阴性菌是主要病原体,大肠埃希菌是主要分离菌,而金黄色葡萄球菌是最常见的革兰阳性菌。阿米卡星和头孢哌酮/舒巴坦似乎是覆盖大多数革兰阴性病原体的初始抗生素,对于疑似革兰阳性菌感染需加用万古霉素。FN是血液系统恶性肿瘤患者发病和死亡的主要原因,高度怀疑及早期经验性使用抗生素并给予支持治疗是降低这些患者高死亡率的主要干预措施。应尽快根据培养药敏报告调整抗生素。